Anthem Biosciences Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO’s Sell rating on Anthem Biosciences Ltd indicates a cautious stance for investors considering this midcap pharmaceutical and biotechnology company. A Sell rating suggests that the stock is expected to underperform relative to the broader market or its sector peers over the medium term. Investors are advised to carefully evaluate the risks and consider alternative opportunities before committing capital.

Rating Update Context

The rating was revised to Sell on 09 March 2026, with the Mojo Score dropping from 50 to 34, signalling a notable decline in the company’s overall assessment. This change reflects a combination of factors including valuation concerns, financial trends, and technical indicators. While the rating change date is important, the analysis below focuses on the company’s current status as of 01 April 2026, ensuring investors have the most up-to-date information.

Quality Assessment

As of 01 April 2026, Anthem Biosciences maintains a good quality grade. This suggests that the company demonstrates solid operational capabilities, a competent management team, and a stable business model within the Pharmaceuticals & Biotechnology sector. The company’s return on equity (ROE) stands at a respectable 17.7%, indicating effective utilisation of shareholder funds to generate profits. This level of quality is a positive foundation but must be weighed against other factors impacting the rating.

Valuation Considerations

Currently, the stock is classified as very expensive based on valuation metrics. The price-to-book value ratio is notably high at 12.9, which implies that the market price significantly exceeds the company’s net asset value. Such a premium valuation can heighten risk, especially if earnings growth does not meet investor expectations. Despite a 35% rise in profits over the past year, the elevated valuation suggests limited upside potential and increased vulnerability to market corrections.

Financial Trend Analysis

The financial grade for Anthem Biosciences is negative as of 01 April 2026. Recent quarterly results highlight some challenges: profit before tax excluding other income (PBT LESS OI) fell by 24.2% to ₹122.31 crores, and profit after tax (PAT) declined by 14.1% to ₹110.87 crores compared to the previous four-quarter average. Additionally, net sales for the quarter were at a low ₹423.15 crores. These figures indicate a weakening financial trend that weighs heavily on the stock’s outlook.

Technical Outlook

The technical grade is assessed as mildly bearish. This reflects recent price movements and market sentiment that suggest some downward pressure or consolidation in the stock price. Over the past month, the stock has declined by 4.65%, while the six-month return is negative at -13.42%. However, shorter-term trends show mixed signals with a 3-month gain of 4.55% and a year-to-date increase of 2.62%. These technical factors contribute to the cautious Sell rating.

Stock Performance Snapshot

As of 01 April 2026, Anthem Biosciences has delivered a 1-day gain of 1.80% and a 1-week increase of 3.41%. Despite these short-term gains, the stock’s longer-term performance remains subdued with a 6-month decline of 13.42%. The absence of a one-year return figure suggests limited data availability or recent volatility. Investors should consider these mixed returns in the context of the company’s fundamentals and valuation.

Implications for Investors

The Sell rating advises investors to approach Anthem Biosciences with caution. While the company exhibits good quality and has shown profit growth, the very expensive valuation and negative financial trends present significant risks. The mildly bearish technical outlook further supports a conservative stance. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector may wish to explore alternatives with stronger financial momentum and more attractive valuations.

Sector and Market Context

Within the Pharmaceuticals & Biotechnology sector, midcap companies like Anthem Biosciences often face volatility due to regulatory changes, research and development outcomes, and competitive pressures. The current market environment demands strong financial discipline and attractive valuations to justify investment. Anthem’s very expensive valuation and recent profit declines contrast with sector peers that may offer more balanced risk-reward profiles.

Summary

In summary, Anthem Biosciences Ltd’s Sell rating by MarketsMOJO, last updated on 09 March 2026, reflects a comprehensive evaluation of quality, valuation, financial trends, and technical factors. As of 01 April 2026, the company shows good operational quality but faces challenges from a stretched valuation and weakening financial performance. The mildly bearish technical signals reinforce the cautious outlook. Investors should carefully weigh these factors when considering Anthem Biosciences for their portfolios.

Looking Ahead

Investors monitoring Anthem Biosciences should watch for improvements in quarterly earnings, valuation adjustments, and technical momentum shifts. Any positive developments in these areas could alter the stock’s outlook. Until then, the Sell rating serves as a prudent guide to manage risk and capital allocation in a dynamic market.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →